Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
- 1 January 2012
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 108 (07), 166-175
- https://doi.org/10.1160/th11-09-0676
Abstract
Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development. The primary objective of the present study was to assess the pharmacodynamics (PD) and safety of enoxaparin 1 mg/kg followed 12 hours (h) post-dose by edoxaban 60 mg, which is the regimen being used in the phase III study of edoxaban for the treatment of venous thromboembolism (Hokusai-VTE). This was a phase I, open-label, randomised, four-period, four-treatment cross-over study. Treatments were edoxaban alone (EDOX), enoxaparin alone (ENOX), edoxaban plus enoxaparin (EDOX+ENOX), and enoxaparin followed by edox aban 12 h later (ENOX12-EDOX). Serial blood samples were collected for PD (thrombin generation, anti-FXa) and pharmacokinetic (PK) variables (edoxaban and its principal metabolite M4 by LC-MS/MS, and anti-FIIa as a surrogate of enoxaparin). The highest effect on thrombin AUC (endogenous thrombin potential, or ETP), thrombin (peak), thrombin generation lag time, and velocity index was observed for EDOX+ENOX, followed by ENOX, ENOX12-EDOX, and EDOX. The greatest effect on anti-FXa activity was observed for EDOX+ENOX, followed by ENOX12-EDOX. As expected, neither edoxaban nor enoxaparin significantly altered the PK of the other drug. There were no serious adverse events during the study. It is concluded that a 60-mg dose of edoxaban can be safely administered 12 h following enoxaparin 1 mg/ kg.Keywords
Funding Information
- Daiichi Sankyo
This publication has 21 references indexed in Scilit:
- Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy VolunteersThe Journal of Clinical Pharmacology, 2011
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysJournal of Thrombosis and Haemostasis, 2011
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 2010
- The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients.Thrombosis and Haemostasis, 2010
- Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparinThrombosis and Haemostasis, 2009
- DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJournal of Thrombosis and Haemostasis, 2008
- Effect of the anti‐factor Xa and anti‐factor IIa activities of low‐molecular‐weight heparins upon the phases of thrombin generationJournal of Thrombosis and Haemostasis, 2007
- Thrombin generation assays: accruing clinical relevanceCurrent Opinion in Hematology, 2004
- Circadian Variation of the Efficacy of Thrombolytic Therapy in Acute Myocardial Infarction—Isn’t the Time Ripe for Cardiovascular Chronotherapy?Angiology, 2004